Tag: NCT03517449

Home / NCT03517449

Categories

Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer

August 2021: Pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) has been approved by the Food and Drug Administration for patients with advanced endometrial carcinoma that...
nct03517449

Scan the code